WO2014006571A2 - Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof - Google Patents
Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof Download PDFInfo
- Publication number
- WO2014006571A2 WO2014006571A2 PCT/IB2013/055433 IB2013055433W WO2014006571A2 WO 2014006571 A2 WO2014006571 A2 WO 2014006571A2 IB 2013055433 W IB2013055433 W IB 2013055433W WO 2014006571 A2 WO2014006571 A2 WO 2014006571A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- levodopa
- carbidopa
- acid
- component
- extended
- Prior art date
Links
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 title claims abstract description 63
- 238000013265 extended release Methods 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 43
- 239000002552 dosage form Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 57
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 57
- 229960004502 levodopa Drugs 0.000 claims abstract description 57
- 229960004205 carbidopa Drugs 0.000 claims abstract description 51
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims abstract description 51
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract description 36
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 8
- 239000011248 coating agent Substances 0.000 claims description 73
- 238000000576 coating method Methods 0.000 claims description 73
- 239000008188 pellet Substances 0.000 claims description 52
- 239000000463 material Substances 0.000 claims description 45
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 42
- 239000000654 additive Substances 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 35
- -1 spheroids Substances 0.000 claims description 24
- 239000002775 capsule Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 14
- 239000003826 tablet Substances 0.000 claims description 14
- 229920001577 copolymer Polymers 0.000 claims description 13
- 238000011049 filling Methods 0.000 claims description 12
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 10
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 10
- 239000011975 tartaric acid Substances 0.000 claims description 10
- 235000002906 tartaric acid Nutrition 0.000 claims description 10
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000004014 plasticizer Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000003605 opacifier Substances 0.000 claims description 3
- 239000008137 solubility enhancer Substances 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- 239000001361 adipic acid Substances 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 229960001484 edetic acid Drugs 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003456 ion exchange resin Substances 0.000 claims description 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000008185 minitablet Substances 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 235000021313 oleic acid Nutrition 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 30
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 24
- 239000006185 dispersion Substances 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 229920003134 Eudragit® polymer Polymers 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 229920000642 polymer Polymers 0.000 description 14
- 239000000454 talc Substances 0.000 description 12
- 229910052623 talc Inorganic materials 0.000 description 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 9
- 239000008213 purified water Substances 0.000 description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 7
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 239000001069 triethyl citrate Substances 0.000 description 7
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 7
- 235000013769 triethyl citrate Nutrition 0.000 description 7
- 238000013270 controlled release Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 229940069328 povidone Drugs 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229920003141 Eudragit® S 100 Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CCGPUGMWYLICGL-UHFFFAOYSA-N Neburon Chemical compound CCCCN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 CCGPUGMWYLICGL-UHFFFAOYSA-N 0.000 description 2
- 206010030312 On and off phenomenon Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229920006318 anionic polymer Polymers 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000008199 coating composition Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 238000005563 spheronization Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- WDQFELCEOPFLCZ-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrolidin-2-one Chemical compound OCCN1CCCC1=O WDQFELCEOPFLCZ-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 description 1
- QPVJXFUHTRULGD-UHFFFAOYSA-N 5-azaniumyl-2-tert-butylpent-2-enoate Chemical compound CC(C(C(=O)[O-])=CCC[NH3+])(C)C QPVJXFUHTRULGD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- HLLIZLQYEKTHHX-UHFFFAOYSA-N CCN.CCOC(C=C)=O.CC(C(OC)=O)=C Chemical compound CCN.CCOC(C=C)=O.CC(C(OC)=O)=C HLLIZLQYEKTHHX-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229940123736 Decarboxylase inhibitor Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- YUXIBTJKHLUKBD-UHFFFAOYSA-N Dibutyl succinate Chemical compound CCCCOC(=O)CCC(=O)OCCCC YUXIBTJKHLUKBD-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000035854 Drug effect decreased Diseases 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical class CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229940078495 calcium phosphate dibasic Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 239000003954 decarboxylase inhibitor Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960002097 dibutylsuccinate Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- IEPRKVQEAMIZSS-AATRIKPKSA-N diethyl fumarate Chemical compound CCOC(=O)\C=C\C(=O)OCC IEPRKVQEAMIZSS-AATRIKPKSA-N 0.000 description 1
- VKNUORWMCINMRB-UHFFFAOYSA-N diethyl malate Chemical compound CCOC(=O)CC(O)C(=O)OCC VKNUORWMCINMRB-UHFFFAOYSA-N 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- JMGZBMRVDHKMKB-UHFFFAOYSA-L disodium;2-sulfobutanedioate Chemical compound [Na+].[Na+].OS(=O)(=O)C(C([O-])=O)CC([O-])=O JMGZBMRVDHKMKB-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960004310 piribedil Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960003179 rotigotine Drugs 0.000 description 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940001089 sinemet Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Definitions
- the present invention relates to extended-release pharmaceutical dosage forms of carbidopa and levodopa comprising: a first component comprising a first portion of carbidopa and levodopa; a second component comprising a second portion of carbidopa and levodopa; and a third component comprising a third portion of carbidopa, levodopa, and carboxylic acid.
- the present invention also relates to processes for the preparation of said extended-release pharmaceutical dosage forms.
- the present invention further relates to a method of treating Parkinson's disease by administering said extended-release pharmaceutical dosage forms.
- Parkinson's disease is caused by the deficiency of dopamine in the brain. Since dopamine is unable to cross the blood-brain barrier, direct preparations comprising dopamine are unable to treat this disease.
- levodopa the immediate precursor of dopamine which can cross the blood-brain barrier, has been used for decades to treat this disease. Since the majority of levodopa can be decarboxylated to dopamine in the peripheral tissues leading to unwanted symptoms, the decarboxylase inhibitor carbidopa had been used in combination with levodopa.
- U.S. Patent No. 8,377,474 discloses a dosage form of carbidopa and levodopa that provides a constant or relatively steady levodopa plasma concentration over a prolonged period of time to optimize relief of symptoms with immediate onset of action. It discloses that the desired release profile can only be achieved when carboxylic acid is present in a distinct and separate component from the carbidopa and levodopa components.
- an extended-release dosage form of carbidopa and levodopa having three distinct components: a first controlled-release component comprising carbidopa, levodopa, and a rate-controlling excipient; a second controlled-release component comprising carboxylic acid and a rate-controlling excipient; and a third immediate-release component comprising carbidopa and levodopa.
- the present invention aims to provide extended-release pharmaceutical dosage forms of carbidopa and levodopa which provide a constant or steady levodopa plasma concentration over a prolonged period of time with decreased motor fluctuations, reduced "off time, and increased “on” time in patients.
- the scientists of the present invention have surprisingly discovered that the desired release profile can still be achieved when carboxylic acid is present in one of the components together with carbidopa and levodopa.
- the present invention includes extended-release pharmaceutical dosage forms of carbidopa and levodopa comprising: a first component comprising a first portion of carbidopa and levodopa; a second component comprising a second portion of carbidopa and levodopa; and a third component comprising a third portion of carbidopa, levodopa, and carboxylic acid.
- the third component of the present invention comprises a core of carboxylic acid.
- the present invention provides constant or steady levodopa plasma concentration over a prolonged period of time with decreased motor fluctuations, reduced "off time, and increased "on" time in patients. It also includes processes for the preparation of said extended-release pharmaceutical dosage forms. It further includes a method of treating Parkinson's disease by administering said extended-release pharmaceutical dosage forms.
- a first aspect of the present invention provides an extended-release pharmaceutical dosage form of carbidopa and levodopa comprising:
- an extended-release pharmaceutical dosage form of carbidopa and levodopa comprising:
- the second component comprises one or more rate-controlling materials and the third component comprises:
- an extended-release coating comprising one or more rate-controlling materials.
- an extended-release pharmaceutical dosage form of carbidopa and levodopa comprising:
- a third component comprising a third portion of carbidopa, levodopa, and carboxylic acid, wherein the first and second components comprise one or more rate-controlling materials and the third component comprises:
- a second aspect of the present invention provides a process for the preparation of an extended-release pharmaceutical dosage form of carbidopa and levodopa, wherein the process comprises the steps of:
- the first component is prepared by a process comprising the steps of:
- step (ii) spheronizing and extruding the blend of step (i) to obtain pellets.
- the second component is prepared by a process comprising the steps of:
- step (ii) spheronizing and extruding the blend of step (i) to obtain pellets
- step (iii) optionally applying a seal coating onto the pellets of step (ii) comprising one or more film- forming polymers and one or more coating additives; and (iv) applying an extended-release coating onto the pellets of step (iii) comprising one or more rate-controlling materials and one or more coating additives.
- the third component is prepared by a process comprising the steps of:
- step (iii) optionally applying the seal coating onto pellets of step (ii) comprising one or more film-forming polymers and one or more coating additives;
- step (iv) applying an immediate -release coating onto the pellets of step (iii) comprising carbidopa, levodopa, and one or more pharmaceutically acceptable excipients; and (v) applying an extended-release coating onto the pellets of step (iv) comprising one or more rate-controlling materials and one or more coating additives.
- a third aspect of the present invention provides a process for the preparation of an extended-release pharmaceutical dosage form of carbidopa and levodopa, wherein the process comprises the steps of:
- the first component is prepared by a process comprising the steps of:
- step (ii) spheronizing and extruding the blend of step (i) to obtain pellets
- step (iii) optionally applying a seal coating onto the pellets of step (ii) comprising one or more film- forming polymers and one or more coating additives;
- the second component is prepared by a process comprising the steps of: (i) blending carbidopa and levodopa with one or more pharmaceutically acceptable excipients;
- step (ii) spheronizing and extruding the blend of step (i) to obtain pellets
- step (iii) optionally applying a seal coating onto the pellets of step (ii) comprising one or more film- forming polymers and one or more coating additives;
- the third component is prepared by a process comprising the steps of:
- step (iii) optionally applying a seal coating onto the pellets of step (ii) comprising one or more film- forming polymers and one or more coating additives;
- step (iv) applying an immediate-release coating onto the pellets of step (iii) comprising carbidopa, levodopa, and one or more pharmaceutically acceptable excipients.
- a fourth aspect of the present invention provides a method of treating Parkinson's disease by administering an extended-release dosage of carbidopa and levodopa comprising:
- a method of treating Parkinson's disease by administering an extended-release dosage of carbidopa and levodopa comprising:
- the method comprises co-administration of one or more drugs known to treat Parkinson's disease selected from the group consisting of entacapone, pramipexole, rasagiline, selegiline, ropinirole, piribedil, bromocriptine, pergolide, lisuride, cabergoline, apomorphine, rotigotine, tolcapone, amantadine, or combinations thereof.
- Parkinson's disease selected from the group consisting of entacapone, pramipexole, rasagiline, selegiline, ropinirole, piribedil, bromocriptine, pergolide, lisuride, cabergoline, apomorphine, rotigotine, tolcapone, amantadine, or combinations thereof.
- the carboxylic acid is either present in the core or is layered on an inert core.
- An example of carboxylic acid present in the core includes pellets of carboxylic acid such as tartaric acid pellets.
- Suitable examples of inert cores are selected from the group consisting of microcrystalline cellulose, sucrose, lactose, maltodextrin, pregelatinized starch, dicalcium phosphate, celphere, or non-pareils.
- the inert cores may be of any geometric shape, though spheres are particularly used for obtaining uniform coating.
- component includes pellets, spheroids, beads, microspheres, seeds, granules, mini tablets, ion-exchange resin beads, or combinations thereof.
- the component is in the form of pellets.
- immediate-release means carbidopa and levodopa are released substantially immediately upon administration with complete dissolution within an hour.
- extended-release means carbidopa and levodopa are released over a prolonged period of time, in particular, over a period of more than an hour.
- carboxylic acid includes all organic acid and salts thereof. Suitable examples of organic acids are selected from the group consisting of tartaric acid, adipic acid, succinic acid, citric acid, benzoic acid, maleic acid, acetic acid, ascorbic acid, edetic acid, fumaric acid, lactic acid, malic acid, oleic acid, sorbic acid, stearic acid, palmitic acid, glutaric acid, glutamic acid, mandelic acid, or mixtures thereof.
- the carboxylic acid is tartaric acid.
- the salts include, but are not limited to, alkali and alkaline earth metal salts such as sodium, potassium, lithium, calcium, strontium, barium, and antimony; the ammo um salts; or the alkanolamme salts.
- Tartaric acid pellets means spherical cores containing a hundred percent of tartaric acid. Tartaric acid pellets act as a pH-modifier, and enhance the solubility for substances with a poor solubility in the higher pH that occurs in the lower gastrointestinal tract. Tartaric acid pellets have been used as a starter core in the pharmaceutical preparations.
- rate-controlling material includes cellulose derivatives such as ethyl cellulose, butyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, cellulose acetate butyrate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl
- vinyl polymers such as polyvinyl chloride, polyvinyl acetate, polyvinyl butyrate, polyvinyl alcohol, polyvinyl pyrrolidones, homopolymer of N-vinyl-2-pyrrolidone, polyvinyl acetate phthalates, N-vinyl-2-pyrrolidone, and polyvinyl ester; polysaccharides such as alginate, xanthan, carrageenan, scleroglucan, pullulan, dextran, hyaluronic acid, chitin, chitosan, and starch; other natural polymers like proteins such as albumin and gelatin; natural rubber; acrylates such as polymethacrylate, poly(hydroxy ethyl methacrylate), poly(methyl methacrylate), and poly(hydroxy ethyl methacrylate-co methyl methacrylate); neutral methacrylic polymers
- the rate-controlling material used in the present invention is a methacrylic acid and methyl methacrylate copolymer. More preferably, the rate-controlling material is a mixture of Eudragit ® L 100, and Eudragit ® S 100 polymers. The ratio of the amounts of the Eudragit ® L 100 to the Eudragit ® S 100 in the coating ranges from about 1 : 1 to about 1 :4.
- Eudragit ® L 100 is a pH-dependent anionic polymer powder solubilizing above pH 6.0 for targeted drug delivery in the jejunum. It is an anionic copolymer derived from methacrylic acid and methyl methacrylate with a ratio of free carboxy groups to ester groups of approximately 1 : 1. Preferably, it has a mean molecular weight of greater than about 100,000 daltons, e.g., about 135,000 daltons.
- Eudragit S 100 is a pH-dependent anionic polymer powder solubilizing above pH 7.0 for targeted drug delivery in the jejunum. It is an anionic copolymer derived from methacrylic acid and methyl methacrylate with a ratio of free carboxy groups to ester groups of approximately 1 :2. Preferably, it has a mean molecular weight of greater than about 100,000 daltons, e.g., about 135,000 daltons.
- the extended-release pharmaceutical dosage forms of the present invention comprise from about 25 mg to about 2000 mg levodopa, preferably from about 50 mg to about 600 mg of levodopa.
- the extended-release pharmaceutical dosage forms of the present invention comprise from about 10 mg to about 300 mg carbidopa, preferably from about 10 mg to about 80 mg of carbidopa.
- all three components comprise carbidopa and levodopa in a weight ratio of about 1 : 1 to about 1 : 10, preferably 1 :4.
- dosage form of the present invention includes tablets or capsules. All the components remain distinct and separate from each other.
- the components can be either filled in a capsule of suitable size or can be compressed together to form a trilayered tablet.
- pharmaceutically acceptable excipient includes excipients that are conventionally used in the pharmaceutical compositions.
- the pharmaceutically acceptable excipients are selected from the group consisting of surfactants, solubility enhancers, fillers, lubricants, binders, disintegrants, coloring agents, plasticizers, and opacifiers.
- the surfactant may be selected from anionic, cationic, or non-ionic surfactants.
- anionic surfactants are selected from the group consisting of sodium lauryl sulfate, dialkyl sodium sulfosuccinate, sodium stearate, potassium stearate, sodium oleate, or mixtures thereof.
- Suitable examples of cationic surfactants are selected from the group consisting of benzalkonium chloride, bis-2-hydroxyethyl oleyl amine, or mixtures thereof.
- non- ionic surfactants are selected from the group consisting of polyoxyethylene sorbitan fatty acid esters; fatty alcohols such as lauryl, cetyl and stearyl alcohols; glyceryl esters such as the naturally occurring mono-, di-, and tri- glycerides; fatty acid esters of fatty alcohols; polyglycolized glycerides such as Gelucire ® ; polyoxyethylene-polyoxypropylene block co-polymer such as poloxamers; other alcohols such as propylene glycol, polyethylene glycol, and cholesterol; or mixtures thereof.
- fatty alcohols such as lauryl, cetyl and stearyl alcohols
- glyceryl esters such as the naturally occurring mono-, di-, and tri- glycerides
- fatty acid esters of fatty alcohols polyglycolized glycerides such as Gelucire ®
- polyoxyethylene-polyoxypropylene block co-polymer such as po
- solubility enhancers are selected from the group consisting of polyethylene glycol, propylene glycol, glycerol, mono-alcohol, higher alcohol, dimethylsulfoxide, dimethylformamide, N, N- dimethylacetamide, 2-pyrrolidone, N-(2- hydroxyethyl) pyrrolidone, N-methylpyrrolidone, 1 -dodecylazacycloheptan-2-one, N- substituted-alkyl azacycloalkyl-2-ones, or mixtures thereof.
- Suitable examples of fillers are selected from the group consisting of lactose, mannitol, pregelatinized starch, calcium carbonate, calcium phosphate dibasic, calcium phosphate tribasic, calcium sulphate, kaolin, starch, or mixtures thereof.
- Suitable examples of lubricants are selected from the group consisting of colloidal silicon dioxide, stearic acid, magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, talc, hydrogenated castor oil, sucrose esters of fatty acid, microcrystalline wax, yellow beeswax, white beeswax, or mixtures thereof.
- Suitable examples of binders are selected from the group consisting of methyl cellulose, low substituted hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone, gelatin, gum arabic, ethyl cellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol, or mixtures thereof.
- Suitable examples of disintegrants are selected from the group consisting of sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, sodium starch glycolate, carboxymethyl cellulose, calcium carboxymethyl cellulose, cross-linked polyvinyl pyrrolidone, croscarmellose sodium, natural, modified, or pregelatinized starch, microcrystalline cellulose, gums such as guar gum, alginic acid, or mixtures thereof.
- Coloring agents includes any FDA approved color for oral use.
- plasticizers are selected from the group consisting of triethyl citrate, dibutyl sebacate, acetylated triacetin, tributyl citrate, glycerol tributyrate, monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin sorbitol, diethyloxalate, diethyl phthalate, diethylmalate, diethyl fumarate, dibutyl succinate, diethyl malonate, dioctyl phthalate, or mixtures thereof.
- opacifiers are selected from the group consisting of titanium dioxide, manganese dioxide, iron oxide, silicon dioxide, or mixtures thereof.
- the different components may be prepared by
- wet granulation dry granulation
- direct compression extrusion-spheronization
- hot melt extrusion hot melt extrusion
- the wet granulation process involves use of water or any other suitable granulating fluid.
- Dry granulation may involve the use of a roller compacter or any suitable technique.
- the different components are prepared by the technique of extrusion-spheronization.
- granulating fluid/solvents for coating include purified water or organic solvents, for example acetone, ethanol, isopropyl alcohol, methylene chloride, or combinations thereof.
- the different components of the present invention may further comprise one or more seal coating layers.
- the seal coating may be present in between different layers or on the top of any component of the present invention.
- the seal coat comprises one or more film- forming polymers which does not have a substantial effect and more preferably, no measurable effect on the release of carbidopa and levodopa.
- Coating additives are selected from the group consisting of plasticizers, lubricants, and coloring agents.
- film-forming polymers include cellulose derivatives such as ethylcellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methylcellulose, carboxymethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, cellulose acetate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, and cellulose acetate trimellitate; waxes; methacrylic acid polymers such as Eudragit ® ; or mixtures thereof.
- commercially available coating compositions comprising film-forming polymers marketed under various trade names, such as Opadry ® , may also be used.
- Coating may be performed by applying the coating composition as a
- Carbidopa, levodopa, microcrystalline cellulose, mannitol, sodium starch glycolate, sodium lauryl sulphate, and povidone were blended together.
- step 2 The blend of step 1 was put into a rapid mixer granulator, and water was added.
- step 2 The wet mass of step 2 was extruded through an extruder, and spheronized a spheronizer to form pellets. 4.
- Eudragit L 100, Eudragit S 100, and triethyl citrate were dissolved in a mixture of isopropyl alcohol, acetone, and purified water to form a solution.
- step 3 The pellets of step 3 were coated with the dispersion of step 5 to form
- step 7 The blend of step 7 was put into a rapid mixer granulator, and water was added.
- step 8 The wet mass of step 8 was extruded through an extruder, and spheronized in a spheronizer to form pellets.
- Eudragit ® L 100, Eudragit ® S 100, and triethyl citrate were dissolved in a mixture of isopropyl alcohol, acetone, and purified water to form a solution.
- step 9 The pellets of step 9 were coated with the dispersion of step 1 1 to form
- a solution of hydroxypropyl methyl cellulose was prepared in an isopropyl alcohol and purified water mixture.
- a solution of hydroxypropyl methyl cellulose was prepared in an isopropyl alcohol and purified water mixture.
- Talc was dispersed into the solution of step 16 to form a dispersion.
- step 15 were coated with the dispersion of step 17.
- Eudragit ® L 100, Eudragit ® S 100, and triethyl citrate were dissolved in a mixture of isopropyl alcohol, acetone, and purified water to form a solution.
- step 18 The pellets of step 18 were coated with the dispersion of step 20.
- a solution of hydroxypropyl methyl cellulose was prepared in purified water and isopropyl alcohol. 23. Talc was dispersed into the solution of step 22 to form a dispersion.
- step 21 The pellets of step 21 were coated with the dispersion of step 23.
- step 27 The pellets of step 24 were coated with the dispersion of step 26.
- step 6 The pellets of step 6, step 12, and step 27 were mixed and filled into a
- Carbidopa, levodopa, croscarmellose sodium, and povidone are blended together.
- step 2 The blend of step 1 is put into a rapid mixer granulator and water is added.
- step 3 The wet mass of step 2 is extruded through a 1.0 mm screen and spheronized.
- step 3 The spheres of step 3 are dried, and screened with suitable mesh to form
- pellets. 5 The pellets of step 4 are blended with magnesium stearate to form immediate-release pellets.
- Carbidopa, levodopa, microcrystalline cellulose, sodium starch glycolate, mannitol, and povidone are blended together.
- step 6 The blend of step 6 is put in a rapid mixer granulator, and water is added.
- step 7 The wet mass of step 7 is extruded through a 1.0 mm screen and spheronized.
- step 8 The spheres of step 8 are dried, and screened with suitable mesh to form
- a solution of hydroxypropyl methyl cellulose is prepared in water, or an organic solvent.
- Talc is dispersed into the solution of step 10 to form a dispersion.
- step 9 The pellets of step 9 are coated with the dispersion of step 1 1.
- Talc is dispersed into the solution of step 13 to form a dispersion.
- step 12 The coated pellets of step 12 are coated with the dispersion of step 14 to form extended-release pellets.
- a Solution of hydroxypropyl methyl cellulose is prepared in water or an organic solvent.
- Eudragit ® L 100, Eudragit ® S 100, and triethyl citrate are dissolved in a
- step 18 The pellets of step 18 are coated with the dispersion of step 20.
- Carbidopa, levodopa, and low substituted hydroxypropyl cellulose are
- step 23 Povidone is dissolved in water to form a binder solution.
- step 24 The pellets of step 21 are taken in a Granurex rotor processor, and coated by spraying the spray powder of step 22 and binder solution of step 23.
- Eudragit ® L 100, Eudragit ® S 100, and triethyl citrate are dissolved in a mixture of isopropyl alcohol and acetone to form a solution.
- Talc is dispersed into the solution of step 25 to form a dispersion.
- step 24 The pellets of step 24 are coated with the dispersion of step 26 to form
- step 28 The pellets of step 5, step 15, and step 27 are mixed and filled into capsules of suitable size.
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to extended-release pharmaceutical dosage forms of carbidopa and levodopa comprising: a first component comprising a first portion of carbidopa and levodopa; a second component comprising a second portion of carbidopa and levodopa; and a third component comprising a third portion of carbidopa, levodopa, and carboxylic acid. The present invention also relates to processes for the preparation of said extended-release pharmaceutical dosage forms. The present invention further relates to a method of treating Parkinson's disease by administering said extended-release pharmaceutical dosage forms.
Description
EXTENDED-RELEASE PHARMACEUTICAL DOSAGE FORMS OF CARBIDOPA AND LEVODOPA AND PROCESSES OF PREPARATION
THEREOF
Field of the Invention
The present invention relates to extended-release pharmaceutical dosage forms of carbidopa and levodopa comprising: a first component comprising a first portion of carbidopa and levodopa; a second component comprising a second portion of carbidopa and levodopa; and a third component comprising a third portion of carbidopa, levodopa, and carboxylic acid. The present invention also relates to processes for the preparation of said extended-release pharmaceutical dosage forms. The present invention further relates to a method of treating Parkinson's disease by administering said extended-release pharmaceutical dosage forms.
Background of the Invention
Parkinson's disease is caused by the deficiency of dopamine in the brain. Since dopamine is unable to cross the blood-brain barrier, direct preparations comprising dopamine are unable to treat this disease. In this regard, levodopa, the immediate precursor of dopamine which can cross the blood-brain barrier, has been used for decades to treat this disease. Since the majority of levodopa can be decarboxylated to dopamine in the peripheral tissues leading to unwanted symptoms, the decarboxylase inhibitor carbidopa had been used in combination with levodopa.
Currently available controlled-release formulation of carbidopa and levodopa, including Sinemet® CR tablets, continuously release the drug over a prolonged period of time. However, the currently available controlled-release formulation shows a considerable delay in the onset of action. Patients face this problem particularly in the morning, when symptoms appear, because most of the last evening's dose gets worn off during the night. Patients suffering from symptoms in the morning are unwilling to take a controlled-release formulation with a delayed onset of action. In such cases, a controlled- release dosage form that could also provide a rapid onset of action would provide an advantage over the current therapy.
U.S. Patent No. 8,377,474 discloses a dosage form of carbidopa and levodopa that provides a constant or relatively steady levodopa plasma concentration over a prolonged
period of time to optimize relief of symptoms with immediate onset of action. It discloses that the desired release profile can only be achieved when carboxylic acid is present in a distinct and separate component from the carbidopa and levodopa components. It further discloses an extended-release dosage form of carbidopa and levodopa having three distinct components: a first controlled-release component comprising carbidopa, levodopa, and a rate-controlling excipient; a second controlled-release component comprising carboxylic acid and a rate-controlling excipient; and a third immediate-release component comprising carbidopa and levodopa.
However, there remains a need in the art to develop alternative dosage forms of carbidopa and levodopa which provide steady levodopa plasma concentration with immediate onset of action, which in turn reduces the "wearing off effect" and "on-off effect".
The present invention aims to provide extended-release pharmaceutical dosage forms of carbidopa and levodopa which provide a constant or steady levodopa plasma concentration over a prolonged period of time with decreased motor fluctuations, reduced "off time, and increased "on" time in patients. By repeated experimentations, the scientists of the present invention have surprisingly discovered that the desired release profile can still be achieved when carboxylic acid is present in one of the components together with carbidopa and levodopa.
Summary of the Invention
The present invention includes extended-release pharmaceutical dosage forms of carbidopa and levodopa comprising: a first component comprising a first portion of carbidopa and levodopa; a second component comprising a second portion of carbidopa and levodopa; and a third component comprising a third portion of carbidopa, levodopa, and carboxylic acid. The third component of the present invention comprises a core of carboxylic acid. The present invention provides constant or steady levodopa plasma concentration over a prolonged period of time with decreased motor fluctuations, reduced "off time, and increased "on" time in patients. It also includes processes for the preparation of said extended-release pharmaceutical dosage forms. It further includes a method of treating Parkinson's disease by administering said extended-release pharmaceutical dosage forms.
Detailed Description of the Invention
A first aspect of the present invention provides an extended-release pharmaceutical dosage form of carbidopa and levodopa comprising:
(a) a first component comprising a first portion of carbidopa and levodopa; (b) a second component comprising a second portion of carbidopa and levodopa; and
(c) a third component comprising a third portion of carbidopa, levodopa, and carboxylic acid.
According to one embodiment of the present invention, there is provided an extended-release pharmaceutical dosage form of carbidopa and levodopa, comprising:
(a) a first component comprising a first portion of carbidopa and levodopa;
(b) a second component comprising a second portion of carbidopa and levodopa; and
(c) a third component comprising a third portion of carbidopa, levodopa, and carboxylic acid
wherein the second component comprises one or more rate-controlling materials and the third component comprises:
(i) a core of carboxylic acid;
(ii) an extended-release coating comprising one or more rate-controlling materials;
(iii) an immediate-release coating comprising carbidopa and levodopa; and
(iv) an extended-release coating comprising one or more rate-controlling materials.
According to another embodiment of the present invention, there is provided an extended-release pharmaceutical dosage form of carbidopa and levodopa, comprising:
(a) a first component comprising a first portion of carbidopa and levodopa;
(b) a second component comprising a second portion of carbidopa and levodopa; and
(c) a third component comprising a third portion of carbidopa, levodopa, and carboxylic acid,
wherein the first and second components comprise one or more rate-controlling materials and the third component comprises:
(i) a core of carboxylic acid;
(ii) an extended-release coating comprising one or more rate-controlling materials; and
(iii) an immediate-release coating comprising carbidopa and levodopa.
A second aspect of the present invention provides a process for the preparation of an extended-release pharmaceutical dosage form of carbidopa and levodopa, wherein the process comprises the steps of:
(a) preparing the first component comprising the first portion of carbidopa, levodopa, and one or more pharmaceutically acceptable excipients;
(b) preparing the second component comprising the second portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives;
(c) preparing the third component comprising the third portion of carbidopa, levodopa, carboxylic acid, one or more rate-controlling materials, one or more pharmaceutically acceptable excipients, and one or more coating additives; and
(d) mixing all the three components and filling the components into a capsule of suitable size or compressing into a tablet.
According to one embodiment of the present invention, there is provided a process for the preparation of an extended-release pharmaceutical dosage form of carbidopa and levodopa, wherein the process comprises the steps of:
(a) preparing the first component comprising the first portion of carbidopa, levodopa, and one or more pharmaceutically acceptable excipients;
(b) preparing the second component comprising the second portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives;
(c) preparing the third component comprising the third portion of carbidopa, levodopa, carboxylic acid, one or more rate-controlling materials, one or
more pharmaceutically acceptable excipients, and one or more coating additives; and
(d) mixing all the three components and filling the components into a capsule of suitable size or compressing into a tablet
wherein the first component is prepared by a process comprising the steps of:
(i) blending carbidopa and levodopa with one or more pharmaceutically acceptable excipients; and
(ii) spheronizing and extruding the blend of step (i) to obtain pellets.
According to another embodiment of the present invention, there is provided a process for the preparation of an extended-release pharmaceutical dosage form of carbidopa and levodopa, wherein the process comprises the steps of:
(a) preparing the first component comprising the first portion of carbidopa, levodopa, and one or more pharmaceutically acceptable excipients;
(b) preparing the second component comprising the second portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives;
(c) preparing the third component comprising the third portion of carbidopa, levodopa, carboxylic acid, one or more rate-controlling materials, one or more pharmaceutically acceptable excipients, and one or more coating additives; and
(d) mixing all the three components and filling the components into a capsule of suitable size or compressing into a tablet
wherein the second component is prepared by a process comprising the steps of:
(i) blending carbidopa and levodopa with one or more pharmaceutically acceptable excipients;
(ii) spheronizing and extruding the blend of step (i) to obtain pellets;
(iii) optionally applying a seal coating onto the pellets of step (ii) comprising one or more film- forming polymers and one or more coating additives; and
(iv) applying an extended-release coating onto the pellets of step (iii) comprising one or more rate-controlling materials and one or more coating additives.
According to another embodiment of the present invention, there is provided a process for the preparation of an extended-release pharmaceutical dosage form of carbidopa and levodopa, wherein the process comprises the steps of:
(a) preparing the first component comprising the first portion of carbidopa, levodopa, and one or more pharmaceutically acceptable excipients;
(b) preparing the second component comprising the second portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives;
(c) preparing the third component comprising the third portion of carbidopa, levodopa, carboxylic acid, one or more rate-controlling materials, one or more pharmaceutically acceptable excipients, and one or more coating additives; and
(d) mixing all the three components and filling the components into a capsule of suitable size or compressing into a tablet
wherein the third component is prepared by a process comprising the steps of:
(i) optionally applying a seal coating comprising one or more film- forming polymers and one or more coating additives onto the pellets of carboxylic acid;
(ii) applying an extended-release coating onto the pellets of step (i)
comprising one or more rate-controlling materials and one or more coating additives;
(iii) optionally applying the seal coating onto pellets of step (ii) comprising one or more film-forming polymers and one or more coating additives;
(iv) applying an immediate -release coating onto the pellets of step (iii) comprising carbidopa, levodopa, and one or more pharmaceutically acceptable excipients; and
(v) applying an extended-release coating onto the pellets of step (iv) comprising one or more rate-controlling materials and one or more coating additives.
A third aspect of the present invention provides a process for the preparation of an extended-release pharmaceutical dosage form of carbidopa and levodopa, wherein the process comprises the steps of:
(a) preparing the first component comprising the first portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives;
(b) preparing the second component comprising the second portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives;
(c) preparing the third component comprising the third portion of carbidopa, levodopa, carboxylic acid, one or more rate-controlling materials, one or more pharmaceutically acceptable excipients, and one or more coating additives; and
(d) mixing all three components and filling the components into a capsule of suitable size or compressing into a tablet.
According to one embodiment of the present invention, there is provided a process for the preparation of an extended-release pharmaceutical dosage form of carbidopa and levodopa, wherein the process comprises the steps of:
(a) preparing the first component comprising the first portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives;
(b) preparing the second component comprising the second portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives;
(c) preparing the third component comprising the third portion of carbidopa, levodopa, carboxylic acid, one or more rate-controlling materials, one or
more pharmaceutically acceptable excipients, and one or more coating additives; and
(d) mixing all three components and filling the components into a capsule of suitable size or compressing into a tablet
wherein the first component is prepared by a process comprising the steps of:
(i) blending carbidopa and levodopa with one or more pharmaceutically acceptable excipients;
(ii) spheronizing and extruding the blend of step (i) to obtain pellets;
(iii) optionally applying a seal coating onto the pellets of step (ii) comprising one or more film- forming polymers and one or more coating additives; and
(iv) applying an extended-release coating onto the pellets of step (iii)
comprising one or more rate-controlling materials and one or more coating additives.
According to another embodiment of the present invention, there is provided a process for the preparation of an extended-release pharmaceutical dosage form of carbidopa and levodopa, wherein the process comprises the steps of:
(a) preparing the first component comprising the first portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives;
(b) preparing the second component comprising the second portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives;
(c) preparing the third component comprising the third portion of carbidopa, levodopa, carboxylic acid, one or more rate-controlling materials, one or more pharmaceutically acceptable excipients, and one or more coating additives; and
(d) mixing all three components and filling the components into a capsule of suitable size or compressing into a tablet
wherein the second component is prepared by a process comprising the steps of:
(i) blending carbidopa and levodopa with one or more pharmaceutically acceptable excipients;
(ii) spheronizing and extruding the blend of step (i) to obtain pellets;
(iii) optionally applying a seal coating onto the pellets of step (ii) comprising one or more film- forming polymers and one or more coating additives; and
(iv) applying an extended-release coating onto the pellets of step (iii)
comprising one or more rate-controlling materials and one or more coating additives.
According to another embodiment of the present invention, there is provided a process for the preparation of an extended-release pharmaceutical dosage form of carbidopa and levodopa, wherein the process comprises the steps of:
(a) preparing the first component comprising the first portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives;
(b) preparing the second component comprising the second portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives;
(c) preparing the third component comprising the third portion of carbidopa, levodopa, carboxylic acid, one or more rate-controlling materials, one or more pharmaceutically acceptable excipients, and one or more coating additives; and
(d) mixing all three components and filling the components into a capsule of suitable size or compressing into a tablet
wherein the third component is prepared by a process comprising the steps of:
(i) optionally applying a seal coating comprising one or more film- forming polymers and one or more coating additives onto pellets of carboxylic acid;
(ii) applying an extended-release coating onto the pellets of step (i)
comprising one or more rate-controlling materials and one or more coating additives;
(iii) optionally applying a seal coating onto the pellets of step (ii) comprising one or more film- forming polymers and one or more coating additives; and
(iv) applying an immediate-release coating onto the pellets of step (iii) comprising carbidopa, levodopa, and one or more pharmaceutically acceptable excipients.
A fourth aspect of the present invention provides a method of treating Parkinson's disease by administering an extended-release dosage of carbidopa and levodopa comprising:
(a) a first component comprising a first portion of carbidopa and levodopa;
(b) a second component comprising a second portion of carbidopa and levodopa; and
(c) a third component comprising a third portion of carbidopa, levodopa, and carboxylic acid.
According to one embodiment of the present invention, there is provided a method of treating Parkinson's disease by administering an extended-release dosage of carbidopa and levodopa comprising:
(a) a first component comprising a first portion of carbidopa and levodopa;
(b) a second component comprising a second portion of carbidopa and levodopa; and
(c) a third component comprising a third portion of carbidopa, levodopa, and carboxylic acid
wherein the method comprises co-administration of one or more drugs known to treat Parkinson's disease selected from the group consisting of entacapone, pramipexole, rasagiline, selegiline, ropinirole, piribedil, bromocriptine, pergolide, lisuride, cabergoline, apomorphine, rotigotine, tolcapone, amantadine, or combinations thereof.
In the present invention, the carboxylic acid is either present in the core or is layered on an inert core. An example of carboxylic acid present in the core includes pellets of carboxylic acid such as tartaric acid pellets. Suitable examples of inert cores are selected from the group consisting of microcrystalline cellulose, sucrose, lactose, maltodextrin, pregelatinized starch, dicalcium phosphate, celphere, or non-pareils. The
inert cores may be of any geometric shape, though spheres are particularly used for obtaining uniform coating.
The term "component", as used herein, includes pellets, spheroids, beads, microspheres, seeds, granules, mini tablets, ion-exchange resin beads, or combinations thereof. Preferably, the component is in the form of pellets.
The term "immediate-release", as used herein, means carbidopa and levodopa are released substantially immediately upon administration with complete dissolution within an hour.
The term "extended-release", as used herein, means carbidopa and levodopa are released over a prolonged period of time, in particular, over a period of more than an hour.
The term "about", as used herein, refers to any value which lies within the range defined by a variation of up to 10% of the value.
The term "carboxylic acid", as used herein, includes all organic acid and salts thereof. Suitable examples of organic acids are selected from the group consisting of tartaric acid, adipic acid, succinic acid, citric acid, benzoic acid, maleic acid, acetic acid, ascorbic acid, edetic acid, fumaric acid, lactic acid, malic acid, oleic acid, sorbic acid, stearic acid, palmitic acid, glutaric acid, glutamic acid, mandelic acid, or mixtures thereof. Preferably, the carboxylic acid is tartaric acid. The salts include, but are not limited to, alkali and alkaline earth metal salts such as sodium, potassium, lithium, calcium, strontium, barium, and antimony; the ammo um salts; or the alkanolamme salts.
The term "tartaric acid pellets", as used herein, means spherical cores containing a hundred percent of tartaric acid. Tartaric acid pellets act as a pH-modifier, and enhance the solubility for substances with a poor solubility in the higher pH that occurs in the lower gastrointestinal tract. Tartaric acid pellets have been used as a starter core in the pharmaceutical preparations.
The term "rate-controlling material" includes cellulose derivatives such as ethyl cellulose, butyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, cellulose acetate butyrate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl
methylcellulose acetate succinate, cellulose acetate, and cellulose propionate; vinyl polymers such as polyvinyl chloride, polyvinyl acetate, polyvinyl butyrate, polyvinyl
alcohol, polyvinyl pyrrolidones, homopolymer of N-vinyl-2-pyrrolidone, polyvinyl acetate phthalates, N-vinyl-2-pyrrolidone, and polyvinyl ester; polysaccharides such as alginate, xanthan, carrageenan, scleroglucan, pullulan, dextran, hyaluronic acid, chitin, chitosan, and starch; other natural polymers like proteins such as albumin and gelatin; natural rubber; acrylates such as polymethacrylate, poly(hydroxy ethyl methacrylate), poly(methyl methacrylate), and poly(hydroxy ethyl methacrylate-co methyl methacrylate); neutral methacrylic polymers such as Eudragit® FS 30 D; methacrylic acid and methyl methacrylate copolymers such as Eudragit® S 100 and Eudragit® L 100; methacrylate copolymers with trimethyl-aminoethyl-methacrylate such as Eudrgait® RL, Eudragit® RS, and Eudragit® NE; Carbopol® 934; ethyl acrylate -methyl methacrylate-ethyl ammonium trimethyl chloride methacrylate copolymer; acrylic acid type polymer having a quaternary ammonium- alky 1 group; ethyl acryalte-methyl methacrylate-ethyl ammonium trimethyl chloride methacrylate copolymer; polyamides such as polyacrylamide and poly(methylene bisacrylamide); polyanhydrides such as poly(biscarboxyphenoxy)methane; PEO-PPO block-co-polymers such as poloxamers; polyethylene glycols and co-polymers thereof; polyethylene oxides and co-polymers thereof; polypropylene and co-polymers thereof; polystyrene; polyesters such as poly(lactic acid), poly(glycolic acid), poly(caprolactone) and co-polymers thereof, and poly(ortho esters), and co-polymers thereof; resins such as Dowen™ and Amberlite®; polycarbonate; cellophane; silicones such as
poly(dimethylsiloxane); shellacs; waxes such as carnauba wax, beeswax, glycowax, and castor wax; stearates such as glycerol monopalmitate, glyceryl monostearate, glyceryl tristearate, and stearyl alcohol; lipids such as glycerides and phospholipids; paraffin; cetyl alcohol; or mixtures thereof. Preferably, the rate-controlling material used in the present invention is a methacrylic acid and methyl methacrylate copolymer. More preferably, the rate-controlling material is a mixture of Eudragit® L 100, and Eudragit® S 100 polymers. The ratio of the amounts of the Eudragit® L 100 to the Eudragit® S 100 in the coating ranges from about 1 : 1 to about 1 :4.
Eudragit® L 100 is a pH-dependent anionic polymer powder solubilizing above pH 6.0 for targeted drug delivery in the jejunum. It is an anionic copolymer derived from methacrylic acid and methyl methacrylate with a ratio of free carboxy groups to ester groups of approximately 1 : 1. Preferably, it has a mean molecular weight of greater than about 100,000 daltons, e.g., about 135,000 daltons.
Eudragit S 100 is a pH-dependent anionic polymer powder solubilizing above pH 7.0 for targeted drug delivery in the jejunum. It is an anionic copolymer derived from methacrylic acid and methyl methacrylate with a ratio of free carboxy groups to ester groups of approximately 1 :2. Preferably, it has a mean molecular weight of greater than about 100,000 daltons, e.g., about 135,000 daltons.
The extended-release pharmaceutical dosage forms of the present invention comprise from about 25 mg to about 2000 mg levodopa, preferably from about 50 mg to about 600 mg of levodopa. The extended-release pharmaceutical dosage forms of the present invention comprise from about 10 mg to about 300 mg carbidopa, preferably from about 10 mg to about 80 mg of carbidopa. In the present invention, all three components comprise carbidopa and levodopa in a weight ratio of about 1 : 1 to about 1 : 10, preferably 1 :4.
The term "dosage form" of the present invention includes tablets or capsules. All the components remain distinct and separate from each other. The components can be either filled in a capsule of suitable size or can be compressed together to form a trilayered tablet.
The term "pharmaceutically acceptable excipient", as used herein, includes excipients that are conventionally used in the pharmaceutical compositions. The pharmaceutically acceptable excipients are selected from the group consisting of surfactants, solubility enhancers, fillers, lubricants, binders, disintegrants, coloring agents, plasticizers, and opacifiers.
The surfactant may be selected from anionic, cationic, or non-ionic surfactants. Suitable examples of anionic surfactants are selected from the group consisting of sodium lauryl sulfate, dialkyl sodium sulfosuccinate, sodium stearate, potassium stearate, sodium oleate, or mixtures thereof. Suitable examples of cationic surfactants are selected from the group consisting of benzalkonium chloride, bis-2-hydroxyethyl oleyl amine, or mixtures thereof. Suitable examples of non- ionic surfactants are selected from the group consisting of polyoxyethylene sorbitan fatty acid esters; fatty alcohols such as lauryl, cetyl and stearyl alcohols; glyceryl esters such as the naturally occurring mono-, di-, and tri- glycerides; fatty acid esters of fatty alcohols; polyglycolized glycerides such as Gelucire®;
polyoxyethylene-polyoxypropylene block co-polymer such as poloxamers; other alcohols such as propylene glycol, polyethylene glycol, and cholesterol; or mixtures thereof.
Suitable examples of solubility enhancers are selected from the group consisting of polyethylene glycol, propylene glycol, glycerol, mono-alcohol, higher alcohol, dimethylsulfoxide, dimethylformamide, N, N- dimethylacetamide, 2-pyrrolidone, N-(2- hydroxyethyl) pyrrolidone, N-methylpyrrolidone, 1 -dodecylazacycloheptan-2-one, N- substituted-alkyl azacycloalkyl-2-ones, or mixtures thereof.
Suitable examples of fillers are selected from the group consisting of lactose, mannitol, pregelatinized starch, calcium carbonate, calcium phosphate dibasic, calcium phosphate tribasic, calcium sulphate, kaolin, starch, or mixtures thereof.
Suitable examples of lubricants are selected from the group consisting of colloidal silicon dioxide, stearic acid, magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, talc, hydrogenated castor oil, sucrose esters of fatty acid, microcrystalline wax, yellow beeswax, white beeswax, or mixtures thereof.
Suitable examples of binders are selected from the group consisting of methyl cellulose, low substituted hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone, gelatin, gum arabic, ethyl cellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol, or mixtures thereof.
Suitable examples of disintegrants are selected from the group consisting of sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, sodium starch glycolate, carboxymethyl cellulose, calcium carboxymethyl cellulose, cross-linked polyvinyl pyrrolidone, croscarmellose sodium, natural, modified, or pregelatinized starch, microcrystalline cellulose, gums such as guar gum, alginic acid, or mixtures thereof.
Coloring agents includes any FDA approved color for oral use.
Suitable examples of plasticizers are selected from the group consisting of triethyl citrate, dibutyl sebacate, acetylated triacetin, tributyl citrate, glycerol tributyrate, monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin sorbitol, diethyloxalate, diethyl phthalate, diethylmalate, diethyl fumarate, dibutyl succinate, diethyl malonate, dioctyl phthalate, or mixtures thereof.
Suitable examples of opacifiers are selected from the group consisting of titanium dioxide, manganese dioxide, iron oxide, silicon dioxide, or mixtures thereof.
In the present invention, the different components may be prepared by
conventional techniques known in the art such as wet granulation, dry granulation, direct compression, extrusion-spheronization, or hot melt extrusion. The wet granulation process involves use of water or any other suitable granulating fluid. Dry granulation may involve the use of a roller compacter or any suitable technique. Preferably, the different components are prepared by the technique of extrusion-spheronization.
Specific examples of granulating fluid/solvents for coating include purified water or organic solvents, for example acetone, ethanol, isopropyl alcohol, methylene chloride, or combinations thereof.
The different components of the present invention may further comprise one or more seal coating layers. The seal coating may be present in between different layers or on the top of any component of the present invention. The seal coat comprises one or more film- forming polymers which does not have a substantial effect and more preferably, no measurable effect on the release of carbidopa and levodopa.
Coating additives are selected from the group consisting of plasticizers, lubricants, and coloring agents.
Examples of film-forming polymers include cellulose derivatives such as ethylcellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methylcellulose, carboxymethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, cellulose acetate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, and cellulose acetate trimellitate; waxes; methacrylic acid polymers such as Eudragit®; or mixtures thereof. Alternatively, commercially available coating compositions comprising film-forming polymers marketed under various trade names, such as Opadry®, may also be used.
Coating may be performed by applying the coating composition as a
solution/dispersion/blend using any conventional coating technique known in the art such as spray coating in a conventional coating pan or fluidized bed processor or Granurex® rotor processor, dip coating, or compression coating.
The invention may be further illustrated by the following examples, which illustrative purposes only and should not be construed as limiting the scope of the invention in any way.
EXAMPLES
Example 1 :
First Component
Second Component
Third Component
Procedure:
First Component
1. Carbidopa, levodopa, microcrystalline cellulose, mannitol, sodium starch glycolate, sodium lauryl sulphate, and povidone were blended together.
2. The blend of step 1 was put into a rapid mixer granulator, and water was added.
3. The wet mass of step 2 was extruded through an extruder, and spheronized a spheronizer to form pellets.
4. Eudragit L 100, Eudragit S 100, and triethyl citrate were dissolved in a mixture of isopropyl alcohol, acetone, and purified water to form a solution.
5. Talc was dispersed into the solution of step 4 to form a dispersion.
6. The pellets of step 3 were coated with the dispersion of step 5 to form
extended-release pellets of the first component.
Second Component
7. Carbidopa, levodopa, and microcrystalline cellulose were blended together.
8. The blend of step 7 was put into a rapid mixer granulator, and water was added.
9. The wet mass of step 8 was extruded through an extruder, and spheronized in a spheronizer to form pellets.
10. Eudragit® L 100, Eudragit® S 100, and triethyl citrate were dissolved in a mixture of isopropyl alcohol, acetone, and purified water to form a solution.
1 1. Talc was dispersed into the solution of step 10 to form a dispersion.
12. The pellets of step 9 were coated with the dispersion of step 1 1 to form
extended-release pellets of the second component.
Third Component
13. A solution of hydroxypropyl methyl cellulose was prepared in an isopropyl alcohol and purified water mixture.
14. Talc was dispersed into the solution of step 13 to form a dispersion.
15. Tartaric acid pellets were coated with the dispersion of step 14.
16. A solution of hydroxypropyl methyl cellulose was prepared in an isopropyl alcohol and purified water mixture.
17. Talc was dispersed into the solution of step 16 to form a dispersion.
18. The pellets of step 15 were coated with the dispersion of step 17.
19. Eudragit® L 100, Eudragit® S 100, and triethyl citrate were dissolved in a mixture of isopropyl alcohol, acetone, and purified water to form a solution.
20. Talc was dispersed into the solution of step 19 to form a dispersion.
21. The pellets of step 18 were coated with the dispersion of step 20.
22. A solution of hydroxypropyl methyl cellulose was prepared in purified water and isopropyl alcohol.
23. Talc was dispersed into the solution of step 22 to form a dispersion.
24. The pellets of step 21 were coated with the dispersion of step 23.
25. A solution of hydroxypropyl methyl cellulose was prepared in purified water.
26. Carbidopa and levodopa were dispersed into the solution of step 25.
27. The pellets of step 24 were coated with the dispersion of step 26.
Capsule Filling
28. The pellets of step 6, step 12, and step 27 were mixed and filled into a
capsule of suitable size.
Example 2:
First Component
Second Component
Third Component
Procedure:
First Component
1. Carbidopa, levodopa, croscarmellose sodium, and povidone are blended together.
2. The blend of step 1 is put into a rapid mixer granulator and water is added.
3. The wet mass of step 2 is extruded through a 1.0 mm screen and spheronized.
4. The spheres of step 3 are dried, and screened with suitable mesh to form
pellets.
5. The pellets of step 4 are blended with magnesium stearate to form immediate-release pellets.
Second Component
6. Carbidopa, levodopa, microcrystalline cellulose, sodium starch glycolate, mannitol, and povidone are blended together.
7. The blend of step 6 is put in a rapid mixer granulator, and water is added.
8. The wet mass of step 7 is extruded through a 1.0 mm screen and spheronized.
9. The spheres of step 8 are dried, and screened with suitable mesh to form
pellets.
10. A solution of hydroxypropyl methyl cellulose is prepared in water, or an organic solvent.
11. Talc is dispersed into the solution of step 10 to form a dispersion.
12. The pellets of step 9 are coated with the dispersion of step 1 1.
13. Eudragit® L 100, Eudragit® S 100, and triethyl citrate are dissolved in a
mixture of isopropyl alcohol and acetone to form a solution.
14. Talc is dispersed into the solution of step 13 to form a dispersion.
15. The coated pellets of step 12 are coated with the dispersion of step 14 to form extended-release pellets.
Third Component
16. A Solution of hydroxypropyl methyl cellulose is prepared in water or an organic solvent.
17. Talc and mannitol are dispersed into the solution of step 16 to form a
dispersion.
18. Tartaric acid pellets are coated with the dispersion of step 17.
19. Eudragit® L 100, Eudragit® S 100, and triethyl citrate are dissolved in a
mixture of isopropyl alcohol and acetone to form a solution.
20. Talc is dispersed into the solution of step 19 to form a dispersion.
21. The pellets of step 18 are coated with the dispersion of step 20.
22. Carbidopa, levodopa, and low substituted hydroxypropyl cellulose are
blended to form a spray powder.
23. Povidone is dissolved in water to form a binder solution.
24. The pellets of step 21 are taken in a Granurex rotor processor, and coated by spraying the spray powder of step 22 and binder solution of step 23.
25. Eudragit® L 100, Eudragit® S 100, and triethyl citrate are dissolved in a mixture of isopropyl alcohol and acetone to form a solution.
26. Talc is dispersed into the solution of step 25 to form a dispersion.
27. The pellets of step 24 are coated with the dispersion of step 26 to form
extended-release pellets.
Capsule Filling
28. The pellets of step 5, step 15, and step 27 are mixed and filled into capsules of suitable size.
Claims
1. An extended- release pharmaceutical dosage form of carbidopa and levodopa comprising:
(a) a first component comprising a first portion of carbidopa and levodopa; (b) a second component comprising a second portion of carbidopa and levodopa; and
(c) a third component comprising a third portion of carbidopa, levodopa, and carboxylic acid.
2. The extended-release pharmaceutical dosage form according to claim 1 , wherein the second component comprises one or more rate-controlling materials and the third component comprises:
(i) a core of carboxylic acid;
(ii) an extended-release coating comprising one or more rate-controlling materials;
(iii) an immediate-release coating comprising carbidopa and levodopa; and (iv) an extended-release coating comprising one or more rate-controlling materials.
3. The extended- release pharmaceutical dosage form according to claim 1, wherein both the first and second components comprise one or more rate-controlling materials and the third component comprises:
(i) a core of carboxylic acid;
(ii) an extended-release coating comprising one or more rate-controlling materials; and
(iii) an immediate-release coating comprising carbidopa and levodopa.
4. A process for the preparation of an extended-release pharmaceutical dosage form of carbidopa and levodopa, wherein the process comprises the steps of:
(a) preparing the first component comprising the first portion of carbidopa, levodopa, and one or more pharmaceutically acceptable excipients;
(b) preparing the second component comprising the second portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives;
(c) preparing the third component comprising the third portion of carbidopa, levodopa, carboxylic acid, one or more rate-controlling materials, one or more pharmaceutically acceptable excipients, and one or more coating additives; and
(d) mixing all the three components, and filling the components into a capsule of suitable size or compressing into a tablet.
5. A process for the preparation of an extended-release pharmaceutical dosage form of carbidopa and levodopa, wherein the process comprises the steps of:
(a) preparing the first component comprising the first portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives; (b) preparing the second component comprising the second portion of carbidopa, levodopa, one or more rate-controlling materials, one or more
pharmaceutically acceptable excipients, and one or more coating additives; (c) preparing the third component comprising the third portion of carbidopa, levodopa, carboxylic acid, one or more rate-controlling materials, one or more pharmaceutically acceptable excipients, and one or more coating additives; and
(d) mixing all the three components and filling the components into a capsule of suitable size or compressing into a tablet.
6. The extended-release pharmaceutical dosage form according to any of the preceding claims, wherein the rate-controlling material is a methacrylic acid and methyl methacrylate copolymer.
7. The extended-release pharmaceutical dosage form according to any of the preceding claims, wherein the carboxylic acid is selected from the group consisting of tartaric acid, adipic acid, succinic acid, citric acid, benzoic acid, maleic acid, acetic acid, ascorbic acid, edetic acid, fumaric acid, lactic acid, malic acid, oleic acid, sorbic acid, stearic acid, palmitic acid, giutaric acid, glutamic acid, maxideiic acid, or mixtures thereof.
8. The extended-release pharmaceutical dosage form according to any of the preceding claims, wherein the component is selected from the group consisting of pellets,
spheroids, beads, microspheres, seeds, granules, mini tablets, ion-exchange resin beads, or combinations thereof.
9. The extended-release pharmaceutical dosage form according to any of the preceding claims, wherein the components are either filled into a capsule of suitable size or compressed to a trilayered tablet.
10. The extended-release pharmaceutical dosage form according to any of the preceding claims, wherein the pharmaceutically acceptable excipients are selected from the group consisting of surfactants, solubility enhancers, fillers, lubricants, binders, disintegrants, coloring agents, plasticizers, and opacifiers.
11. The extended-release pharmaceutical dosage form according to any of the preceding claims, wherein the coating additives are selected from the group consisting of plasticizers, lubricants, and coloring agents.
12. A method of treating Parkinson's disease by administering an extended-release dosage of carbidopa and levodopa comprising:
(a) a first component comprising a first portion of carbidopa and levodopa; (b) a second component comprising a second portion of carbidopa and levodopa; and
(c) a third component comprising a third portion of carbidopa, levodopa, and carboxylic acid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2064/DEL/2012 | 2012-07-02 | ||
IN2064DE2012 | 2012-07-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014006571A2 true WO2014006571A2 (en) | 2014-01-09 |
WO2014006571A3 WO2014006571A3 (en) | 2014-03-20 |
Family
ID=49170756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2013/055433 WO2014006571A2 (en) | 2012-07-02 | 2013-07-02 | Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014006571A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3184101A1 (en) | 2015-12-21 | 2017-06-28 | Sandoz Ag | Levodopa and carbidopa modified release composition |
CN114762684A (en) * | 2021-01-14 | 2022-07-19 | 华益泰康药业股份有限公司 | Sustained-release capsule for treating Parkinson and preparation method thereof |
WO2024078607A1 (en) * | 2022-10-14 | 2024-04-18 | 浙江华海药业股份有限公司 | Pharmaceutical composition for treating parkinson's disease and preparation method therefor |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8377474B2 (en) | 2007-12-28 | 2013-02-19 | Impax Laboratories, Inc. | Controlled release formulations of levodopa and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070148238A1 (en) * | 2005-06-23 | 2007-06-28 | Spherics, Inc. | Dosage forms for movement disorder treatment |
AR055106A1 (en) * | 2005-08-05 | 2007-08-08 | Osmotica Pharmaceutical Argent | SOLID PHARMACEUTICAL COMPOSITION OF EXTENDED LIBERATION CONTAINING CARBIDOPA AND LEVODOPA |
-
2013
- 2013-07-02 WO PCT/IB2013/055433 patent/WO2014006571A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8377474B2 (en) | 2007-12-28 | 2013-02-19 | Impax Laboratories, Inc. | Controlled release formulations of levodopa and uses thereof |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3184101A1 (en) | 2015-12-21 | 2017-06-28 | Sandoz Ag | Levodopa and carbidopa modified release composition |
CN114762684A (en) * | 2021-01-14 | 2022-07-19 | 华益泰康药业股份有限公司 | Sustained-release capsule for treating Parkinson and preparation method thereof |
CN114762684B (en) * | 2021-01-14 | 2023-11-21 | 华益泰康药业股份有限公司 | Sustained-release capsule for treating parkinsonism and preparation method thereof |
WO2024078607A1 (en) * | 2022-10-14 | 2024-04-18 | 浙江华海药业股份有限公司 | Pharmaceutical composition for treating parkinson's disease and preparation method therefor |
Also Published As
Publication number | Publication date |
---|---|
WO2014006571A3 (en) | 2014-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102356190B1 (en) | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | |
KR101157220B1 (en) | Gastroresistant pharmaceutical formulations containing rifaximin | |
US10973783B2 (en) | Methods and compositions for the treatment of seizure-related disorders | |
AU2014332024A1 (en) | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | |
JP2008520736A5 (en) | ||
JP6759426B2 (en) | Stabilized formulation of CNS compounds | |
US20130195973A1 (en) | Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof | |
WO2012101653A2 (en) | Modified release pharmaceutical compositions memantine | |
AU2017252410A1 (en) | Oral pharmaceutical compositions of mesalazine | |
WO2003101432A1 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
CA2967647A1 (en) | Pharmaceutical bead formulations comprising dimethyl fumarate | |
JP5138932B2 (en) | Modafinil modified release pharmaceutical composition | |
WO2014006571A2 (en) | Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof | |
EP2533766A2 (en) | Pharmaceutical mini-tablets for sustained release of flecainide acetate | |
EP2488162A2 (en) | Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof | |
WO2014174387A1 (en) | Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof | |
WO2011064797A2 (en) | Controlled release pharmaceutical compositions of galantamine | |
EP3796908A1 (en) | Controlled release propiverine formulations | |
CA2984235C (en) | Rivastigmine-containing sustained-release pharmaceutical composition | |
EP3184101A1 (en) | Levodopa and carbidopa modified release composition | |
JP2013536832A (en) | Milnacipran controlled release pharmaceutical composition | |
WO2016088041A1 (en) | Extended-release cefpodoxime proxetil composition | |
US20080299189A1 (en) | Controlled release dopamine agonist compositions | |
EP3389642A1 (en) | Pulsatile release pharmaceutical composition comprising naftazone or one of its salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13762567 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct app. not ent. europ. phase |
Ref document number: 13762567 Country of ref document: EP Kind code of ref document: A2 |